This meta-analysis assessed the use of the neutrophil-to-lymphocyte ratio (NLR) as a means of early detection of contrast-induced nephropathy (CIN) following diagnostic or therapeutic procedures. We used Web of Science, PubMed, and Scopus to conduct a systematic search. There was no limitation regarding language or date of publication. We reported standardized mean difference (SMD) with a 95% confidence interval (CI). Due to high heterogeneity, a random-effects model was used, and the Newcastle–Ottawa scale was used for quality assessment. Thirty-one articles were included in the analysis. Patients in the CIN group had elevated levels of NLR compared with those in the non-CIN group (SMD = 0.78, 95% CI = 0.52–1.04, P < .001). Similar results were observed in either prospective (SMD = 1.03, 95% CI = 0.13–1.93, P = .02) or retrospective studies (SMD = 0.70, 95% CI = 0.45–0.96, P < .001). The pooled sensitivity of NLR was 74.02% (95% CI = 66.54%–81.02%), and the pooled specificity was 60.58% (95% CI = 53.94%–66.84%). NLR shows potential as a cost-effective biomarker for predicting CIN associated with contrast-involved treatments. This could help implement timely interventions to mitigate CIN and improve outcomes.

中文翻译：

---

中性粒细胞与淋巴细胞比率在造影剂肾病中的预后作用：系统评价和荟萃分析

这项荟萃分析评估了中性粒细胞与淋巴细胞比率（NLR）作为诊断或治疗程序后早期检测造影剂肾病（CIN）的手段的用途。我们使用 Web of Science、PubMed 和 Scopus 进行系统检索。语言或出版日期没有限制。我们报告了具有 95% 置信区间 (CI) 的标准化平均差 (SMD)。由于异质性较高，采用随机效应模型，并采用纽卡斯尔-渥太华量表进行质量评估。分析中纳入了 31 篇文章。与非 CIN 组患者相比，CIN 组患者的 NLR 水平升高（SMD = 0.78，95% CI = 0.52–1.04，P < .001）。在前瞻性研究（SMD = 1.03，95% CI = 0.13–1.93，P = .02）或回顾性研究（SMD = 0.70，95% CI = 0.45–0.96，P < .001）中观察到类似的结果。NLR 的汇总敏感性为 74.02%（95% CI = 66.54%–81.02%），汇总特异性为 60.58%（95% CI = 53.94%–66.84%）。NLR 显示出作为一种经济高效的生物标志物的潜力，可用于预测与造影剂相关治疗相关的 CIN。这有助于及时实施干预措施，以减轻 CIN 并改善预后。